NCT04416191 Immune Cells During Disuse and Recovery
| NCT ID | NCT04416191 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Utah |
| Condition | Muscle Disuse |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2022-05-15 |
| Primary Completion | 2027-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 45 participants in total. It began in 2022-05-15 with a primary completion date of 2027-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an interventional study enrolling healthy individuals aged 18-35 and 60-85 to understand the recovery of muscle health following a period of inactivity. The enrollment goal is 45 participants. The study will occur over the course of 1-2 months where participants will undergo testing before and after a 2-week limb immobilization period.
Eligibility Criteria
Inclusion Criteria: 1. Age between 18-35 and 60-85 yrs 2. Ability to sign informed consent 3. Free-living, prior to admission Exclusion Criteria: * History of cardiovascular disease (e.g., CHF, CAD, right-to-left shunt) * History of endocrine or metabolic disease such as hypo/hyperthyroidism and diabetes * History of kidney disease or failure * Vascular disease * Risk of DVT including family history of thrombophilia, DVT, pulmonary emboli, myeloproliferative diseases including polycythemia (Hb\>18 g/dL) or thrombocytosis (platelets\>400x103/mL), and connective tissue diseases (positive lupus anticoagulant), hyperhomocystinemia, deficiencies of factor V Leiden, proteins S and C, and antithrombine III * Use of anticoagulant therapy (e.g., Coumadin, heparin) * Elevated systolic pressure \>150 or a diastolic blood pressure \> 100 * Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators) * Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma * Currently on a weight-loss diet * Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids are permitted) * Androgens or growth hormone within 6 months of enrollment and for study duration (topical physiologic androgen replacement is permitted) * History of stroke with motor disability * A recent history (\<12 months) of GI bleed * History of liver disease * History of respiratory disease (acute upper respiratory infection, history of chronic lung disease) * Pregnancy as determined by a pregnancy test * Any staff members who report directly to an investigator or who report to someone who reports directly to an investigator. * Any other condition or event considered exclusionary by the PI and faculty physician
Contact & Investigator
Micah Drummond, PhD
PRINCIPAL INVESTIGATOR
University of Utah
Frequently Asked Questions
Who can join the NCT04416191 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Muscle Disuse. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04416191 currently recruiting?
Yes, NCT04416191 is actively recruiting participants. Contact the research team at micah.drummond@hsc.utah.edu for enrollment information.
Where is the NCT04416191 trial being conducted?
This trial is being conducted at Salt Lake City, United States.
Who is sponsoring the NCT04416191 clinical trial?
NCT04416191 is sponsored by University of Utah. The principal investigator is Micah Drummond, PhD at University of Utah. The trial plans to enroll 45 participants.